Global Stock Markets

AstraZeneca shares plunged 8.9% following reports of talks regarding a $400 billion mega-merger with US rival Bristol Myers Squibb, continuing market reaction to the potential transaction first reported yesterday. The market sell-off reflects investor concern that acquiring a $133 billion rival forces AstraZeneca to absorb heavy debt while inheriting Bristol Myers' patent cliff, as sales of its key cancer drug Opdivo face a steep drop by 2030. This market reaction contrasts with AstraZeneca's guidance targeting $80 billion in annual revenue by 2030, supported by 20 major clinical readouts over the next 18 months. Analysts at Jefferies criticized the financial engineering, arguing the drugmaker does not require a takeover, while no reported sources defended the transaction's commercial logic. Merging the two companies would also trigger protracted scrutiny from US competition regulators over market concentration in oncology. This bearish thesis would be invalidated if AstraZeneca shares recover above pre-announcement levels or if management clarifies terms that preserve standalone balance sheet strength.

Visa agreed to acquire Israeli fraud detection startup BioCatch for $2.4 billion in cash from Permira and other investors to expand its value-added services business. Generative artificial intelligence has driven global scam and account takeover losses above $1 trillion annually, prompting payment networks to integrate behavioral biometrics like keystroke timing before transactions occur. By incorporating BioCatch's software, which currently protects 760 million users across 350 banks, Visa aims to offer automated defense tools to its network of nearly 14,500 financial institutions processing over 329 billion transactions worth $17 trillion. The deal enhances security for banking clients while diversifying Visa beyond traditional transaction fees into high-margin security subscriptions.

CapVest-backed Curium agreed to acquire Nasdaq-listed radiopharmaceutical developer Lantheus in an all-cash take-private transaction valued at up to nearly $8 billion. Under the terms, Curium will pay $102.50 per share plus up to $12.00 in contingent value rights tied to commercial milestones by 2030, representing a 38% premium over Lantheus' 60-day volume-weighted average price. The transaction combines Curium’s global manufacturing footprint with Lantheus' US commercial infrastructure in prostate diagnostics and radiodiagnostics across oncology, neurology, and cardiology in over 70 countries. The expanded manufacturing platform directly impacts hospital purchasing departments and clinical care providers by accelerating patient access to specialized nuclear medicine and targeted radioligand therapies.